

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2008

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida
(State or other
jurisdiction of
incorporation)

000-27836
(Commission
File Number)

65-0643773
(IRS Employer
Identification No.)

**2 Snunit Street
Science Park
POB 455**

Carmiel, Israel 20100

(Address of principal executive offices) (Zip Code)

(Former Name or Former Address, if Changed Since Last Report)

Registrant's telephone number, including area code: +972-4-988-9488

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure

On July 31, 2008, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that the Company will present at the Oppenheimer Small and Mid Cap Clinical and Regulatory Conference in New York City on Monday, August 4, 2008 at 9:30 a.m. The Company will also participate in a panel entitled “Designing a Pivotal Program with an Eye Towards Approval” at 9:55 a.m. A copy of the press release is furnished as Exhibit 99.1 to this Report.

Item 9.01. Financial Statements and Exhibits**(d) Exhibits**

99.1 Press release dated July 31, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: August 1, 2008

By: /s/ David Aviezer
Name: David Aviezer, Ph.D.
Title: President and
Chief Executive Officer

Protalix BioTherapeutics to Present at the Oppenheimer Small and Mid Cap Clinical and Regulatory Conference

CARMIEL, Israel, July 31, 2008 (Business Wire) — Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it will present at the Oppenheimer Small and Mid Cap Clinical and Regulatory Conference in New York City on August 4, 2008. The conference is being held at Oppenheimer's offices located at 300 Madison Ave. Dr. David Aviezer, Protalix's President and Chief Executive Officer will give a corporate overview at 9:30 AM ET and will participate on the "Designing a Pivotal Program with an Eye Towards Approval" panel at 9:55 AM ET.

Webcasts of the corporate presentation and panel will be available on Protalix's website at www.protalix.com under the events calendar section.

About Protalix BioTherapeutics

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its pivotal phase III clinical trial in Israel, Europe the United States and other locations for its lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Contact:

The Trout Group, LLC

Marcy Strickler, 646-378-2927

mstrickler@troutgroup.com